Dronedarone improves microvascular flow during atrial fibrillation and reduces the infarct size in acute models of myocardial infarction. However, dronedarone might be harmful in patients with recent decompensated heart failure and increases mortality in patients with permanent atrial fibrillation. A pathophysiological explanation for these discrepant data is lacking. This study investigated the effects of dronedarone on gene and protein expression in the infarcted area and border zone in pigs subjected to anterior ischemia/reperfusion myocardial infarction. The ischemia/reperfusion myocardial infarction was induced in 16 pigs. Eight pigs were treated with dronedarone for 28 days after myocardial infarction, the remaining pigs served as control. Microarray-based transcriptome profiling and 2D-DIGEbased proteome analysis were used to assess the effects of dronedarone on left ventricular gene expression in healthy (LV), infarcted (MI), and border zone tissue. Selected targets were validated by RT-qPCR or immunoblot analyses, with special emphasize given to the transcriptome/proteome overlap. Combined "omics" analysis was performed to identify most significant disease and function charts affected by dronedarone and to establish an integrated network. The levels of 879 (BZ) or 7 (MI) transcripts and 51 (LV) or 15 (BZ) proteins were significantly altered by dronedarone, pointing to a substantial efficacy of dronedarone in the border zone. Transcriptome and proteome data indicate that dronedarone influences post-infarction remodeling processes and identify matricellular proteins as major targets of dronedarone in this setting. This finding is fully supported by the disease and function charts as well as by the integrated network established by combined "omics". Dronedarone therapy alters myocardial gene expression after acute myocardial infarction with pronounced effects in the border zone. Dronedarone promotes infarct healing via regulation of periostin and might contribute to the limitation of its expansion as well as cardiac rupture. Thus, there are no experimental hints that dronedarone per se has direct harmful effects after MI in ventricular tissue.
Introduction
Dronedarone is an antiarrhythmic drug for treatment of atrial fibrillation (AF). Data from the ATHENA (a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with AF/atrial flutter) study showed that dronedarone therapy reduces cardiovascular mortality, hospitalization, and incidence of myocardial infarction in patients with AF. 1 The incidence of acute coronary syndromes was also reduced in patients with coronary artery disease (CAD) at baseline as a subgroup analyses revealed. 2 However, dronedarone has been shown to be harmful in patients with recent decompensated heart failure, 3 and according to the PALLAS (permanent AF outcome study using dronedarone on top of standard therapy) study, dronedarone therapy increases mortality in patients with permanent AF, and doubles the rate of the first composite co-primary outcome such as stroke, myocardial infarction, and systemic embolism in these particular patients. 4 In line with their increased risk for subsequent ischemic events, 5 AF patients exhibit a reduced coronary flow reserve (CFR). 6, 7 Benzofuran derivatives such as dronedarone (or amiodarone) have been shown to increase coronary flow 8, 9 and to largely prevent the AF-dependent decline of the CFR during acute RAP in vivo. 10 Dronedarone also reduced the infarct size in models of acute myocardial infarct (MI) in pigs as well as of cerebral infarct in rat. 11, 12 The aim of this study was to elucidate in a model of ischemia/reperfusion myocardial infarction in pigs the effects of dronedarone on the transcriptome and proteome of healthy, infarcted, and border-zone myocardium after 28 days of recovery. Furthermore, an integrated "omics" approach was applied to identify (in a hypothesis-free and unbiased manner) molecular targets and pathways that underlie dronedarone-mediated effects on infarcted, border-zone, or healthy tissue.
Methods Acute myocardial infarction model
All animal care and experimental procedures were approved by the Landesverwaltungsamt Sachsen-Anhalt (Az42502-2-1117-IMTR); 16 pigs were subjected to anterior ischemia/reperfusion MI as described in detail recently. 13 Eight pigs were treated with dronedarone for four weeks after MI, the remaining pigs served as control. At day 28, tissue samples were taken from healthy left ventricular (LV) and right ventricular (RV) myocardium as well as from LV myocardium from the infarct area (MI) or the border zone (BZ). Tissue samples from untreated pigs were designated accordingly as LV, RV, MI or BZ, whereas those obtained from dronedarone-treated pigs were designated LV-D, RV-D, MI-D, or BZ-D, respectively. Designation of samples and sites of sample collection are illustrated in Figure 1 . Tissue samples were immediately frozen in liquid nitrogen and used for transcriptome profiling, RT-qPCR, proteome, and immunoblot analyses as described below. The experimental design is shown in Online Supplement 8.
Microarray array expression analysis
Transcriptome analyses were performed using the GeneChip Porcine Genome Arrays (Affymetrix Inc., Santa Clara, CA, USA). Expression profiling was done at the level of single RNA samples for LV, LV-D, MI, MI-D, BZ, and BZ-D (n ¼ 3 for all groups). Target preparation and hybridization were performed exactly as previously described. 10 Microarray data and statistical analysis Data were analyzed as described recently. 10 Significant differences in gene expression were identified using the following cut-off criteria: one-way analysis of variance with subsequent Benjamini and Hochberg false discovery rate multiple-testing correction on pair-wise comparisons, (ANOVA, P 0.05), signal correction statistics (ratio builder, P 0.05), and fold-change !1.5-fold (for a complete list of significantly regulated genes, see Online Supplement Table 1 ). The improved annotation information for porcine expressed sequences provided by Couture et al.
14 was used.
In silico-pathway-and functional analysis of microarray data
In-silico-pathway-and functional analysis of differentially expressed genes was carried out using the commercial systems biology oriented package Ingenuity Pathways Analysis (Ingenuity Systems, Inc. CA, USA) using the annotation details provided by Couture et al. 14 with their corresponding gene identifiers and expression values.
Reverse transcription quantitative PCR
Reverse transcription quantitative PCR (RT-qPCR) was applied to validate several specific candidate genes resulting from the microarray analyses. Reactions were performed as previously described. 15, 16 Quantities of RPL mRNA were used to normalize cDNA contents. The specific primers applied are listed in Online Supplement 3.
Immunoblot analyses
Experiments were performed as previously described. 15, 16 Twenty micrograms of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies followed by incubation with horseradish peroxidaseconjugated secondary antibodies (used antibodies are summarized in Online Supplement 4). Enhanced chemiluminescence substrate dura (Pierce, Rockford, USA) was used for detection and the AlphaEaseFC software (AlphaImager System, Alpha Innotech, CA, USA) was applied for quantification.
Histochemistry and immunohistochemistry
Cardiac tissue was fixed in 4% neutral-buffered formalin, dehydrated and embedded in paraffin. Staining of 2-mm slides by histochemistry and immunohistochemistry was performed as follows: sections were deparaffinized with xylene and ethanol and stained with AFOG (acid fuchsin orange G) according to standard protocol or treated with primary antibodies (anti-POSTN-ab polyclonal from Sigma-Aldrich, 1:200 diluted), peroxidase-conjugated secondary antibody, and diaminobenzidine substrate.
2D-DIGE coupled mass spectrometry
Two-dimensional-differential in gel electrophoresis.
Comparative proteome analysis of BZ, LV, and their respective dronedarone-treated tissues were analyzed as previously described. 17 Quantified protein extracts were minimally labeled using the Refraction-2D TM -kit according to the manufactures' suggestions (NH DyeAGNOSTICS GmbH, Halle/S., Germany) before electrophoresis. Individual heart protein extracts, 50 lg each (n ¼ 4 per group) were labeled with 400 pmol of either G-200 or G-300 dyes. As an internal standard, aliquots of all individual samples were pooled and labeled with G-100. The labeling of the samples was done by dye swapping such that protein extracts from two animals per group were labeled with G-200 and G-300 each.
Two-dimensional gel electrophoresis was performed as previously described.
18,19
Image analysis and statistical tests. After separation in the second dimension, the gel images were recorded on a Typhoon 9400 Scanner (GE Healthcare) and analyzed with Delta 2D software version 4.0 (Decodon, Greifswald, Germany). After matching the gels, the spot volumes were analyzed by Delta2D and the TMEV (Multi Experiment Viewer) statistic module of the same software package. Statistically significant differences in spot intensities among the groups consisting of four individual biological replicates each were calculated by one-way ANOVA applying Welch t-test with a P-value cutoff of 0.05. 20 In-gel digestion of proteins and mass spectrometric analysis. Preparative gels were run each with 450 lg of the pooled samples. Protein spots were visualized by colloidal Coomassie staining as described in Thiele et al. 18 and images were recorded and aligned with those of analytical gels in Delta2D. The protein spots displaying significant changes were excised from the preparative gels, tryptically digested and separated with a nano-HPLC (EASY-nLC, Proxeon Biosystems A/S, Odense, Denmark) coupled with LTQ-Orbitrap-XL mass spectrometer (Thermo Electron, Bremen, Germany) as previously described. 21 Figure 1. Macroscopic and histologic findings compared to MTI scan and assignment of samples. Photograph of a slice of a swine heart (left) with the respective AFOG-stained sections (overlaid in Adobe Photoshop) compared to the corresponding MRI image (Osirix). Prior to fixation, samples were taken from healthy left ventricular (LV), healthy right ventricular (RV), infarcted left ventricular (MI), or peri-infarct region (border-zone; BZ) tissues, respectively. The exact assignment of samples has been verified by examining the exact positions of biopsy sites the samples were taken from by (I) macroscopic and histologic analysis of swine heart tissue slices and (II) by comparing it to the corresponding MRI image from the whole heart MRI. Biopsy sites are clearly visible and allow for precise allocation of, e.g. RV (bottom) and BZ (top) samples. Identification of proteins. Identification of proteins from 2D-spots was performed via automated SORCERER/ SEQUEST search (Sorcerer built 4.04, Sage-N Research Inc., Milpitas, CA, USA) against a sus scrofa subset of the UniProtKB/Swiss-Prot 2017_05 database with a mass tolerance of 10 ppm (1 Da for fragment ions). Proteins identified with at least two peptides throughout the whole dataset at a peptide prophet probability of 90%. 22 
Statistical analysis
Microarray data and statistical analysis are explained in detail in the microarray methods above. RT-qPCR data were analyzed statistically using the GraphPad Prism software. Data are shown as the median with 25th and 75th percentile. Comparisons between two groups were performed with unpaired t test and between multiple groups using two-way analysis of variance with Tukey's post hoc test adjusting for multiple comparisons, considering P < 0.05 significant.
Results

Haemodynamics and physiology
Hemodynamic parameters and infarct size have been previously described 13 and were not different between the groups. LV ejection fraction was significantly reduced by 30% in the control group (42.26 vs. 29.78%; P ¼ 0.012) and 35% in the dronedarone-treated group (46.89 vs. 30.22%; P ¼ 0.012) following four weeks of infarct healing. 13 
AMI-dependent transcriptome alterations in MI and BZ
Microarray-based mRNA profiling revealed that in response to AMI, there are substantial less changes in transcript levels in the BZ (639 gene specific probe sets) than in MI (3300), when compared with LV. There was an overlap of 589 probe sets with similar mRNA level alterations both in BZ and MI. Complete lists of the corresponding genes are given in Online Supplement 5, data sheets: MI, BZ, and Overlap_MI_BZ, respectively.
Impact of dronedarone on the AMI-specific transcriptome in MI and BZ
Dronedarone modified the AMI-specific transcriptome but the effects were almost exclusively confined to the BZ in which 879 gene-specific probe sets displayed altered levels in response to dronedarone treatment (BZ-D vs. BZ). Only minor effects were seen for the MI (seven gene-specific probe sets differing in level between MI-D vs. MI). significantly affected by dronedarone under conditions of AMI. Pathways showing highest significance levels include ephrin receptor signaling, hepatic fibrosis signaling, PKA signaling, adherence junction signaling, integrin signaling, role of leukocytes and fibroblasts, and inhibition of matrix metalloproteases (BZ) (Online Supplement Table 5 , data sheet ¼ BZ-D vs. BZ_Direct_Pathways).
Due to the low number of significantly dronedaroneaffected transcripts in MI, the overlap of MI and MI-D gene expression changes was compared to identify additional genes partially affected by dronedarone. Thereby, 624 gene-specific probe sets with similar expression change both in MI and MI-D (compared with LV), and with an additional expression change (>15%) in MI-D animals, indicating partial attenuation/aggravation by dronedarone, were identified (Online Supplement 6, data sheet ¼ 15% Change_MI and MI-D).
IPA analysis of these partially affected genes indicated 151 significant canonical pathways (Online Supplement 7, data sheet ¼ MI_MI-D_Pathways). Ephrin receptor signaling, PKA signaling, adherence junction signaling, integrin signaling, mitochondrial dysfunction, and NFAT in cardiac hypertrophy were among those with highest significance levels.
Dronedarone promotes post-infarction cardiac healing and remodeling in BZ Analysis of the effects of dronedarone on the BZ transcriptome identified a panel of genes implicated in different phases of cardiac healing and remodeling. These phases include death of cardiomyocytes, acute inflammation, regression of inflammatory signals, stimulation of ECM production by cardiac fibroblasts, and formation of a mature scar. The individual phases of infarction healing and the assigned dronedarone-affected genes are shown in Figure 3(a) . Although dronedarone exhibits strong effects on the corresponding transcript levels in the BZ, ....................................................................................................................................................... ..... these were not significantly changed in MI-D compared to MI. Apparently, the impact of dronedarone on these genes is much more pronounced in the BZ compared to the MI because in the MI, a considerable fraction of these genes also showed alterations, although to a lesser extent (additional expression change >15% in MI-D; Figure 3(b) ).
Impact of dronedarone on the expression of genes encoding matricellular proteins
Although all phases of infarct healing were affected by dronedarone in the BZ, the majority of dronedaroneaffected genes were related to formation of mature scar (21/ 44, 47.7%), which might well reflect the late time point of analysis (28 days after AMI).
The transcript levels of a large panel of matricellular proteins were significantly altered by dronedarone:
The POSTN-specific transcript levels were significantly increased (2.07-fold) in BZ-D (vs. BZ), and also in MI-D (9.78-fold in MI vs.12.59-fold in MI-D; ¼ 29% additional change by dronedarone, compared to LV). The effect of dronedarone on POSTN in BZ could be clearly validated by RT-qPCR, as was the case for various other target genes related to infarct healing and cardiac remodeling after MI: POSTN (5.75-fold, P ¼ 0.0025), TGFB3 (2.32-fold, P ¼ 0.0215), THBS2 (2.45-fold, P ¼ 0.0215), THBS3 (2.12-fold, P ¼ 0.0405), FN1 (2.19-fold, P ¼ 0.0215), COL8A1 (2.77-fold, P ¼ 0.0504) in BZ. In addition, a slight but non-significant dronedarone-mediated increase could be observed for THBS1 (1.36-fold, P ¼ 0.2455) and TNC (1.33-fold, P ¼ 0.1725) mRNA levels in BZ (Figure 4 ). Compared to the BZ, mRNA levels appeared to be much less affected by dronedarone in the LV. ............................................................................................................................................................ 
2D-DIGE coupled mass spectrometry
Altogether 2214 distinct protein spots were detected in LV/ RV/BZ by 2D-DIGE experiments. Of those, the amounts of 51, 41, and 15 proteins in LV, RV, and BZ, respectively, were identified to be altered by dronedarone treatment (1.2-fold, P < 0.05). There was an overlap of only three proteins between LV and BZ, and of 10 proteins between LV and RV, while 1 protein was affected by dronedarone in all three tissues (Table 1) .
In the BZ, as already observed in the transcriptome analyses, dronedarone provoked significant changes in the expression of genes encoding proteins associated with different phases of post-infarction cardiac healing and remodeling ( Table 2 ). The dronedarone-affected proteins included serpin isoforms, PDIA2, CES1, isoforms of PDIA3, fatty acid-binding protein FABP4, and Ca-binding protein S100 ( Figure 5 ). Immunoblot analysis of selected targets confirmed the observed dronedarone-mediated increase in TGFBR1, COL6A1, HSPA5, THBS1/2, RAD23A, CALD1, and POSTN protein amounts in the BZ, whereas much less expression changes could be observed in the LV (increased TGFBR1 and AT2A2) (Figure 6(a) ).
Remarkably, the immunoblot analyses demonstrated increased POSTN protein levels in the BZ-D as compared to BZ (Figure 6(a) ). However, a similar difference could not be detected by immunostaining of cardiac tissue sections from control and dronedarone-treated pigs (Figure 6(b) ). Providing a possible explanation for this apparent discrepancy, 2D-immunoblot analysis revealed distinct changes in the isoelectric point and apparent molecular weight of POSTN in response to dronedarone, which is consistent with an increased spot intensity of 95 and 68 kDa, approximately, POSTN immunoreactivity in both 1D-and 2D-immunoblot ( Figure 6(c) ).
Integrated omics: Compared ingenuity pathway analysis of transcriptome and proteome data
Although there has been observed a partial overlap only of proteins and transcripts differentially expressed in response to dronedarone (Table 2 ), the canonical pathways that have been identified by single analysis of either proteome or transcriptome data were partly identical. These common canonical pathways include hepatic fibrosis, ILK-signaling, actin cytoskeleton signaling, calcium signaling, cardiac hypertrophy signaling. In order to identify the most relevant networks and canonical pathways, an integrated approach was applied by combining transcriptome and proteome data. This led to a substantial increase of the significance level (two to six orders of magnitude) for a number of IPA Disease and Tox Function Charts (Figure 7) . Among the top 10 disease charts are now skeletal and muscular disorders, cardiovascular disease, and cardiovascular system development (Figure 7(a) ). With respect to Tox Function Charts, cardiac fibrosis, cardiac dysfunction, and cardiac infarction were among the top 10 that manifested as the most relevant (Figure 7(b) ).
Next, to enhance the power of proposed dronedaroneaffected networks, combined omics data were used to build a condensed integrated network. Of note, molecular targets identified before in single omics approach-derived networksand that have already been verified in immunoblot or RTqPCR analyses (Figures 4 and 6(a) ) -reappeared in this novel integrated network (Online Supplement 1). Thereby, additional weight could be added to the relevance of verified targets such as collagens, thrombospondins, tenascin C, SERCA2 (ATP2A2), and TGFb receptor 1 in particular. The functional association of these verified targets is illustrated in the network shown in Online Supplement 2, which again emphasizes the role of matricellular proteins and ECM as major targets of dronedarone in post AMI tissue remodeling.
Discussion
The results of the present study identify the infarction BZ as an important, if not predominant, target of dronedarone in a model of AMI. Results of transcriptome analyses implicate dronedarone in the differential expression of genes involved in various phases of cardiac healing process. 23 Data obtained from proteome analysis confirmed the rather selective effects of dronedarone on protein levels in BZ. Of the dronedarone-affected proteins in the BZ (15 proteins significantly changed (1.2-fold, P < 0.05), 181 changed proteins (1.2-fold, P ¼ n.s.)), 23 exhibited a similar response at transcript level. The post-infarction healing response is a complex process that involves both the infarcted and noninfarcted myocardium and is closely intertwined with ventricular remodeling, resulting in dilation, hypertrophy, and enhanced sphericity of the ventricle. 24, 25 Healing of the infarcted heart comprised distinct, but partially overlapping phases: cardiomyocyte death, inflammatory phase, regression of inflammation, stimulation of ECM, and formation of mature scar. Results of our transcriptome analyses imply that 28 days after AMI there is (I) differential expression of genes that could be assigned to the different phases of infarct healing, which is (II) more pronounced in the BZ when compared to MI, and (III) which is further enhanced by dronedarone in the BZ (BZ-D). Notably, the late phase of mature scar formation appeared to be modulated by dronedarone in particular (21 of 44 genes attributed to this phase). This is in full accordance with substantial effects that dronedarone exerts on the expression of matricellular proteins and ECM, a finding that is actually reflected by the Disease Charts and Tox Function Charts actually regulated by dronedarone.
Massive loss of cardiomyocytes occurs rapidly after AMI. Nevertheless, we clearly observed effects of dronedarone on expression of genes assigned to cell death, in particular within the BZ: PSRC1 (6.06-fold), NDFIP1 (6.05-fold), TNFAIP6 (3.39-fold), LAMP2 (3.1-fold), CASP4 (1.92-fold), CASP3 (1.77-fold) and PTPN13 (1.68-fold) even 28 days after infarction. This indicates that cardiac remodeling processes are still ongoing at this time point. Dronedarone had no significant efficacy in MI, but partially affected the expression of PTPN13 (7.2% additional aggravated expression change in MI-D). Considering the well-established temporal sequence of pathomorphological changes after AMI, cell death-associated gene expression signatures observed here rather reflect cellular depletion as typically Table 1 . Proteins significantly changed by dronedarone (1.2-fold, P < 0.05) in LV, RV, and BZ as determined by 2D-DIGE analysis. ........................................................................................................................................................ ..... observed during the late phase of infarct healing, formation of a mature scar. CASP3 and CASP4 (caspase-3 and -4), members of the pro-inflammatory family of caspases, are key mediators of apoptosis and inflammation, also during MI. The protein tyrosine phosphatase encoded by PTPN13 exerts pro-apoptotic effects via IRS-1/PI3K/Akt signaling, while PSRC1 specifies a proline-rich protein regulated by p53 and participates in p53/TP53-regulated growth suppression. 26 NDFIP1 encodes a putative NFjB and MAPKactivating protein that controls cell growth and nuclear localization of PTEN, and thus cell division and survival. NDFIP1 mutant mice suffered larger infarct sizes following cerebral ischemia, 27 and the gene product of LAMP2
(continued)
(lysosome-associated membrane protein 2) has been associated, e.g., with autophagy in skeletal muscle of infarcted rats. 28 In this study, dronedarone increased mRNA amounts of ATP2B4, ATP2B1, TRDN and decreased that of ATP2A2 after AMI. This is indicative of increased cytoplasmic Ca 2þ levels, which may translate into elevated mitochondrial matrix Ca 2þ levels, compromised OXPHOS, increased ROS levels, and cell death. Supporting this view, increased mRNA amounts of PRDX1, GSTA4, GSTM3, and ENC1, all encoding antioxidants and detoxification enzymes induced by elevated levels of ROS, were observed in BZ-D. ........................................................................................................................................................... 
....
Dronedarone's effects on the inflammatory phase of infarct healing were evidenced by significantly increased expression of CXCL6, IL6, IL23R, HCK, CXCL9, and IL1R1 in BZ-D. Again, dronedarone lacked significant efficacy in MI, but partially changed IL1R1 mRNA levels (43.4% in MI-D). Eventually, the inflammatory phase is limited by anti-inflammatory counter-regulatory mechanisms to maintain tissue integrity and stability to a certain extent. In this context, the activity of matricellular proteins, ECM, and enzymes contributing in tissue remodeling is required to facilitate repair or even partial functional recovery. The results of single omics approaches and of the integrated omics approach in particular, identified a considerable number of such ECM and matricellular proteins as major targets of dronedarone. This view is strengthened by the fact that the top 10 IPA Disease Charts and Tox Function Charts affected by dronedarone are indeed related to cardiac remodeling and repair processes. Many of the underlying molecular targets do represent the transcriptome/proteome overlap or constitute the established integrated Chilukoti et al. Dronedarone regulated infarction border-zone remodeling 905 network (Online Supplement 1). The protein encoded by TNFAIP6 (also known as TSG-6, tumor necrosis factor a-induced protein 6) gene is a multifunctional 35 kDa glyco-protein and a member of the hyaluronate-binding protein family (hyaladherins). Its over-expression limits inflammatory responses in many pathological settings including MI. Here, significantly elevated mRNA amounts of TNFAIP6 (3.39-fold) were observed in BZ-D, and dronedarone attenuated its expression in MI (34.6% increase in MI-D). Hyaladherins are involved in ECM stability and cell migration. 29 Recombinant TNFAIP6 reduced inflammation and infarct size in experimental AMI. 30 Other genes encoding anti-inflammatory and immunosuppressive cytokines that were significantly induced by dronedarone included TGFB3 (transforming growth factor-beta isoform 3) and IL27ra (interleukin 27 receptor alpha). The latter protein mediates anti-inflammatory effects via JAK/STAT signaling. Notably, a significant increase in STAT3 mRNA was observed in BZ-D.
TGF-b, a potent anti-inflammatory cytokine, functions as "master switch" for transition from inflammation to fibrosis. Intracellular Ca 2þ levels regulate TGF-b signaling. The levels of matricellular protein-coding transcript, thrombospondin (TSP/THBS)-1, a key activator of TGF-b, were induced in BZ-D and partially affected in MI-D. 31 Thrombospondins, THBS1 in particular, crucially affect maturation of the infarct scar and prevent expansion of MI.
31 THBS1 expression is elevated during early phases of cardiac healing. By activating TGFB1, THBS1 suppresses inflammatory chemokines/cytokines and prevents leakage ............................................................................................................................................................ of inflammatory process into the non-infarcted region.
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THBS2 encoded protein is secreted predominantly by fibroblasts and shows strongest induction during later stages of post-infarct healing. Although not activating TGFB1, THBS2 crucially determinates integrity of ECM during scar maturation. THBS2 À/À mice are prone to cardiac rupture after MI due to abnormal collagen fibrillogenesis.
33
TGFB1 stimulates the transformation of fibroblasts into activated fibroblasts or myofibroblasts that proliferate and secrete ECM for scar formation. Interestingly, the genes encoding SMAD2, a key downstream modulator of BMP/ TGFb-signaling, and SMURF1, an ubiquitin-ligase that is specific for receptor-regulated SMAD proteins, were substantially induced in BZ-D, with partial impact also in MI-D. TGFB1 and fibroblast growth factor-2 (FGF2) synergistically enhance ECM production. FGF2/FGFR2 protects ischemic and/or infarcted myocardium. 34 We observed an increased expression of FGFR2 in BZ-D.
TGF-b isoforms, upon activation by THBS1 and binding to the receptor, lead to the phosphorylation of SMAD2/3 and subsequent dimerization with SMAD4. This activates ECM gene expression. We demonstrate increased expression of characteristic myofibroblast genes, including POSTN, FN1, CTGF, and TNC encoding periostin, fibronectin, connective tissue growth factor, and tenascin-C, respectively, as well as of SPARC encoding secreted protein, acidic and rich in cysteine (alias osteonectin). More than half of dronedarone-regulated target genes belong to Formation of the mature scar and ECM stimulation phases, and are constituents of Disease Charts and Tox Function Charts and, therefore, of the integrated network. Again, this suggests that genes encoding ECM members and matricellular proteins, such as COL8A1, TNN, GPNMB, LMNA, ACAN, COL1A2, VCAN, COMP, COL8A1, COL12A1, COL6A1, COL16A1, COL5A1, COL5A2, and COL1A1, contribute to dronedarone-dependent alterations of structure and stability of repaired myocardium and/or scar tissue. Of note, collagens 6A1, 6A2, and 6A3 were identified as regulated at the proteome level and COL6A1 and COLA3 are even constituents of the "overlap" (transcriptome 1.5-fold, P < 0.05; proteome 1.2-fold, P < 0.05). This assignment to the "overlap" together with the high abundancy of various collagens in the resulting "integrated network" (collagens I, III, IV, V, VI, VIII, XII; Online Supplement 1 and 2) identifies these collagens and other matricellular proteins as "major" (key targets) dronedarone-regulated targets.
A marked but transient up-regulation of TNC and FN1 in the infarct area has been reported during the proliferative phase of healing. 35 The protein encoded by SPARC regulates infarction healing and collagen maturation by Chilukoti et al. Dronedarone regulated infarction border-zone remodeling 907 direct interaction with collagen type I fibers or by interference with the assembly of fibronectin into fibrils. In our study, ITGAV, ITGA8, ITGBL1, and ITGB3 encoding integrin subunits were induced in response to AMI, where ITGA8 was significantly induced in BZ-D.
Accumulating evidence establishes periostin encoded by POSTN as a crucial player in chronic cardiac remodeling after MI. 23, 36, 37 Periostin which contains four fasciclin domains, promotes cellular adhesion and movement and collagen fibrillogenesis. It modulates collagen deposition, fibrosis, and scar mechanics. 38 Of note, these processes are fully covered in the top Disease Charts and Tox Function Charts that have been identified by the combined omics approach. Decreased periostin plasma levels were associated with AMI, 39 but the protein promotes cardiac repair after MI as indicated by improved ventricular remodeling and myocardial function, reduced fibrosis and infarct size, as well as increased angiogenesis. 40, 41 POSTN À/À mice exhibit impaired cardiac healing and increased mortality after AMI because of cardiac rupture due to reduced myocardial stiffness and impaired collagen formation. 36, 42 Paradoxically, surviving POSTN-deficient mice show less fibrosis and improved cardiac performance. 36, 42 These data imply that periostin might be essential for post-AMI cardiac healing.
Dronedarone could affect periostin-dependent cardiac healing and remodeling after AMI by different, potentially overlapping, mechanisms. Firstly, periostin might regulate the integrity of the ECM through its ability to bind multiple ECM proteins, such as those encoded by TNC and FN1 as well as collagen V, collagen I, aggrecan, and heparin, thereby affecting the structural integrity of the heart matrix or stretch-sensitive signaling. 43, 44 This view is supported by short sized, disorganized and less efficiently cross-linked collagen fibrils and disorganized ECM in POSTN-deficient mice. 45, 46 In addition, periostin promotes collagen cross-linking through BMP1-mediated proteolytic activation of LOX on the extracellular matrix. 44 Thus, by altering the composition and performance of the ECM, periostin affects cardiac healing and remodeling after MI. Secondly, periostin could modulate adhesion-dependent signaling by binding to the integrins avb3, avb5, and a4b6 and transducing signals into the infarct region that activate migration of cardiac fibroblasts through FAK phosphorylation. Migrated cells differentiate into aSMA-positive fibroblasts and contribute to strengthening of the wall stiffness through collagen synthesis and changes of collagen crosslinking and quality. 40, 42, 45 Recent data imply that different isoforms of periostin function to regulate reactive fibrosis in remote regions and replacement fibrosis in infarct tissue in a distinct manner. 46, 47 This might explain some inconsistent results that have been obtained in previous studies. Dronedarone increased POSTN mRNA levels in both healthy LV and BZ. In the BZ, dronedarone led to a substantial increase of periostin protein in immunoblot analysis. This increase was not observed by immunohistochemical analysis of cardiac tissue slices. The hypothesis that this discrepancy is due to dronedarone-dependent protein modifications was supported by the alterations of periostin mobility observed in 2D analysis.
Dronedarone was developed as an antiarrhythmic drug and, thus, might affect ion channel expression. Indeed, a very recent study demonstrates increased protein expression of KIR2.1 in response to dronedarone which results from impaired backward trafficking and decreased degradation. 48 Accordingly, mRNA levels were not altered by dronedarone. 48 The observed increase in mRNA levels of KCNMA1, KCNE1, KCNQ1, KCNH2 provoked by dronedarone in our study (Online Supplement 6), therefore seems to reflect an increase in the fraction of cardiomyocytes in the tissue rather than an induction of gene expression.
The present study has some limitations. First, analyses have been performed at one time point only. The consistent results obtained by transcriptomics, proteomics, and also of combined omics identified significant expression changes that exist at this particular time point, at least in the BZ. Future studies may apply single or combined omics to 908 Experimental Biology and Medicine Volume 243 July 2018 evaluate dronedarone's effects on gene/protein expression in a temporal manner. Second, this study is focused on the identification of the molecular targets and signaling hubs that underlie the previously observed effects of dronedarone on microcirculation and infarct size. To this end, a hypothesis-free and unbiased "integrated omics" approach has been applied here. The effects on cardiac electrophysiology and function, and long-term effects on stability and contractility in particular, remain to be addressed in future work.
Conclusions
In summary, our data indicate pronounced efficacy of dronedarone in the infarct border-zone. In the infarct area, dronedarone, although less effective, still showed partial impact on gene expression. However, there are no experimental hints that dronedarone per se has direct harmful effects after induced myocardial infarction in ventricular tissue.
By applying integrated omics analysis, Disease Charts and Tox Function Charts were identified, that associate dronedarone with different cellular/cardiac processes that are employed in, e.g., post-infarction cardiac healing and remodeling processes. Specifically, dronedarone exerted strong effects on the expression of matricellular proteins and ECM, which could explain its impact on among others cardiac fibrosis, cardiac dysfunction, and cardiac infarction as well as cellular movement and cell morphology. This view is supported by the results of an integrated network analysis, which illustrates dronedarone's capability of orchestrating factors and processes of cardiac remodeling and repair. To what extent dronedarone can improve cardiac functionality in the long term, remains to be assessed in future studies. The long-term consequences of dronedarone treatment on cardiac stability and function need to be elucidated fully.
